

MRN: 111012402890,
DOB: 5/24/1940, Sex: F
Visit date: 9/4/2019

Physician
Transplant Hepatology
Progress Notes
Signed
Encounter Date: 9/4/2019

Signed

Expand All Collapse All



Show: [Error! Hyperlink reference not valid.](#)

Manual Template Copied

Added by:

Hover for details

History of Present Illness. [redacted] is a 79 y.o. female referred in consultation with a history of HCC with underlying HCV and cirrhosis (newly diagnosed). She has no hx of blood transfusion in the past. The work up was done in Guatemala where she lives. I reviewed her records. Earlier in the year she had an MRI that revealed no liver lesions but apparently was done without contrast but on her recent triphasic CT she was found to have a Lesion described to be about 4.4 cm, without portal vein thrombosis and and she has only a mild elevation of AFP (and CA19-). She underwent a biopsy and has proven HCC grade 2. CT of chest was done in April and was negative. Her hepatitis C has not been treated.

Past Medical History:

Diagnosis

Date

- Cancer (CMS-HCC)
- Diabetes (CMS-HCC)
- Thyroid disease

Past Surgical History:

Procedure	Laterality	Date
• HYSTERECTOMY		
• LIPOSUCTION in Mexico		1996

History reviewed. No pertinent family history.

Social History

Socioeconomic History

- Marital status: Married
- Spouse name: Not on file
- Number of children: Not on file
- Years of education: Not on file
- Highest education level: Not on file

Social Needs

- Financial resource strain: Not on file
- Food insecurity - worry: Not on file
- Food insecurity - inability: Not on file
- Transportation needs - medical: Not on file
- Transportation needs - non-medical: Not on file

Occupational History

- Not on file

Tobacco Use

- Smoking status: Former Smoker
- Smokeless tobacco: Never Used

Substance and Sexual Activity

- Alcohol use: Not on file
- Drug use: Not on file
- Sexual activity: Not on file

Other Topics

- Concern

Social History Narrative

- Not on file

Review of Systems:

Review of Systems

Constitutional: Positive for malaise/fatigue.
 HENT: Negative.
 Eyes: Negative.
 Respiratory: Negative.

Cardiovascular: Negative.
Gastrointestinal: Negative.
Genitourinary: Negative.
Musculoskeletal: Positive for back pain.

Swelling of ankles

Skin: Positive for itching.
Neurological: Negative.
Endo/Heme/Allergies: Negative.
Psychiatric/Behavioral: Negative.

BP 122/75 | Pulse 85 | Ht 1.651 m (5' 5") | Wt 79.8 kg (175 lb 14.8 oz) | BMI 29.28 kg/m²

Physical Exam

Physical Exam

Constitutional: She is oriented to person, place, and time and well-developed, well-nourished, and in no distress.

HENT:

Head: Normocephalic and atraumatic.

Neck: No JVD present. No thyromegaly present.

Cardiovascular: Normal rate, regular rhythm and normal heart sounds. Exam reveals no gallop and no friction rub.

No murmur heard.

Pulmonary/Chest: Effort normal and breath sounds normal. No respiratory distress. She has no wheezes. She has no rales. She exhibits no tenderness.

Abdominal: Soft. Bowel sounds are normal. She exhibits no distension and no mass. There is no tenderness. There is no rebound and no guarding.

Musculoskeletal: Normal range of motion. She exhibits edema. She exhibits no tenderness or deformity.

Neurological: She is alert and oriented to person, place, and time. No cranial nerve deficit.

Skin: Skin is warm and dry. No rash noted. No erythema. No pallor.

Multiple skin

Psychiatric: Mood, memory, affect and judgment normal.

Allergy: Patient has no allergy information on record.

Medications:

Atacand 32 mg
Torsemide 10 mg
Levotiroxina 150 mg
Dexlansoprazole 60 mg
Vildagliptin/Metformin 50/500 mg

Hepatocellular carcinoma (CMS-HCC)

The lesion is in right lobe, without associated PVT. She was predisposed due to her until now unknown underlying HCV with cirrhosis.

The plan is to review film at tumor board.

Obtain chest CT

Discussed with interventional radiology the best option for local regional therapy.

Chronic hepatitis C virus infection with cirrhosis (CMS-HCC)

Hepatitis C treatment should be deferred until after HCC is treated.



Currently 2 products are plan genotypic and could be used. I would recommend Epclusa for 12 weeks without ribavirin..

With a recent lack box warning regarding use of protease inhibitors and antivirals for hepatitis C I would not use Mavyret.

Family will find out if this product is available in Guatemala.

More than 50% of time was applied to face to face contact in managing and counseling the patient.

Follow up: before departure

Hepatology

Pref Name:
79 y.o., 5/24/1940

Legal Sex: F
Gender ID:
Sex At Birth:
Pref Pronoun:

Attending:
PCP: PCP, UNKNOWN
MRN: 111012402890
Phone: 305-794-4470

Daily MEDD: None
Code: full (default)
Advance Directives: None
Allergies: Adhesive Tape



Laboratory Results

SnapShot

Chart Review

Review Flows...

Results Review

Allergies

History

Problem List

Implants

Demographics

Letters

Lab Inquiry

Component	Latest Ref Rng & Units	9/6/2019	U/L	9/4/2019
WBC	3.5 - 10.5 K/UL			12.0 (H)
RBC	3.80 - 5.20 M/UL			4.91
Hemoglobin	11.6 - 15.4 g/dL			13.4
Hematocrit	34.0 - 45.0 %			43.3
MCV	80 - 99 FL			88
MCH	27.0 - 34.0 pg			27.3
MCHC	32.0 - 35.5 %			30.9 (L)
RDW	11.0 - 15.0 %			18.0 (H)
Platelets	140 - 390 K/UL			279
Mpv	8.8 - 12.1 fL			12.2 (H)
Differential Type				Auto
Reflex Morphology				No
Hepatitis Bs Antibody		Nonreactive (A)		
Hepatitis Bs Antibody Comment		See comment		
Hepatitis B Core Ab, Total	Nonreactive	Nonreactive		
Hepatitis B Core Antibody Comment		See comment		
Hepatitis B Surface Antigen	Nonreactive	Nonreactive		

COMP METABOLIC PANEL - Details

Study Result

Narrative

ORDERING DEPARTMENT: [REDACTED]

Ordering Provider: [REDACTED]

Call Back Phone Number: (312)695-9121

Component Results

Component	Your Value	Standard Range
Sodium	140 mEq/L	133 - 146 mEq/L
Potassium	3.7 mEq/L	3.5 - 5.1 mEq/L
Chloride	109 mEq/L	98 - 109 mEq/L
CO2	25 mEq/L	21 - 31 mEq/L
Calcium	8.2 mg/dL	8.3 - 10.5 mg/dL
Anion Gap	6	5 - 16
Albumin	1.9 g/dL	3.5 - 5.7 g/dL
Urea Nitrogen	19 mg/dL	2 - 25 mg/dL
Creatinine	0.76 mg/dL	0.60 - 1.30 mg/dL
Glucose	96 mg/dL	65 - 100 mg/dL
Total Protein	5.2 g/dL	6.4 - 8.9 g/dL
ALT (SGPT)	31 Unit/L	0 - 52 Unit/L
Alkaline Phos	94 Unit/L	34 - 104 Unit/L
AST (SGOT)	31 Unit/L	0 - 39 Unit/L
Total Bilirubin	0.2 mg/dL	0.0 - 1.0 mg/dL
GFR(African American)	>60 mL/min/1.73m2	>=60 mL/min/1.73m2
GFR(Others)	>60 mL/min/1.73m2	>=60 mL/min/1.73m2

General Information

Ordered by: [REDACTED]

Collected on 09/09/2019 4:34 PM (Blood)

Resulted on 09/09/2019 5:05 PM

Result Status: Final result

This test result has been released by an automatic process.

HCV GENOTYPE LiPA - Details

Study Result

Narrative

[REDACTED]

Component Results

Component	Your Value	Standard Range
Hepatitis C Genotype	Your Value HCV Genotype:_2	

The VERSANT HCV Genotype 2.0 Assay (LiPA) is a line probe assay designed to identify Hepatitis C virus (HCV) genotypes 1 to 6 and their subtypes (1a,1b,2a,2b,3a,3b,3c,3d,4a,4b,4c,4d,5a,6a, and 6b). It utilizes reverse transcription and amplification of the 5' untranslated region (5'UTR) and core region of the Hepatitis C virus genome. The probes, which are bound to a nitrocellulose strip by a poly (T) tail, are specific for the 5'UTR and core region of different HCV genotypes. This test is designed to detect the most common HCV genotypes 1-6, while this assay can detect Genotype 5, due to the rarity of this genotype they will have to be confirmed by a reference laboratory. In addition, this test is designed only to be performed on patients with a positive HCV result. This test is not intended to diagnose the presence of HCV, but to determine the genotype of an already known diagnosis of HCV. This test was developed and its performance characteristics determined by the Northwestern Memorial Hospital Diagnostic Molecular Biology Laboratory. The VERSANT HCV Genotype 2.0 Assay LiPA assay has not been cleared or approved by the U.S. Food and Drug Administration. Since reagents and/or equipment that are not FDA approved are utilized for this testing, these results should only be used adjunctively for patient management.

General Information

Ordered by [REDACTED] MD

Collected on 09/06/2019 12:47 PM (Blood)

Resulted on 09/10/2019 4:11 PM

Urgent

[Redacted]

DOB: [Redacted]

Date: 09/10/2019

ID: QHM018109301

This is a request for Epclusa x 24 weeks of therapy (1 tablet daily for 24 weeks, which is a total of 168 tablets) Brand is not required, it is okay to use the generic. Patient is treatment naïve with decompensated cirrhosis. Her genotype is pending; however, Epclusa is pangenotypic. She needs the medication by Thursday, September 12th. Please expedite this request. All chart notes are attached.

Sincerely,

[Redacted], MD

[Redacted]

[Redacted]

[Redacted]